Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CervoMed Inc. stock logo
CRVO
CervoMed
$8.78
-0.1%
$9.39
$1.80
$22.57
$76.41M-0.231.33 million shs70,942 shs
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
$4.35
+1.2%
$3.96
$2.79
$7.28
$79.56M0.6614,681 shs2,989 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.28
-0.9%
$3.16
$2.57
$6.88
$20.33M0.598,979 shs6,858 shs
OncoCyte Co. stock logo
OCX
OncoCyte
$2.94
+5.0%
$3.02
$1.92
$4.75
$84.08M0.9557,255 shs66,970 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CervoMed Inc. stock logo
CRVO
CervoMed
-0.11%+0.92%-10.41%+281.74%-55.52%
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
-0.55%-2.25%+12.11%+10.66%+43.39%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-0.91%-0.61%+21.93%-20.96%-50.00%
OncoCyte Co. stock logo
OCX
OncoCyte
+5.00%+6.14%+3.52%+6.52%+6.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CervoMed Inc. stock logo
CRVO
CervoMed
3.3747 of 5 stars
4.44.00.00.01.81.70.6
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
1.5212 of 5 stars
3.53.00.00.00.01.70.0
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.7228 of 5 stars
0.03.00.00.01.81.70.6
OncoCyte Co. stock logo
OCX
OncoCyte
2.3904 of 5 stars
3.34.00.00.02.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CervoMed Inc. stock logo
CRVO
CervoMed
2.89
Moderate Buy$27.63214.64% Upside
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
3.00
Buy$25.00474.71% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
2.67
Moderate Buy$4.4250.23% Upside

Current Analyst Ratings Breakdown

Latest NAII, OCX, GNTA, and CRVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/13/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
5/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$14.00 ➝ $15.00
4/8/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
3/28/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
3/26/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/25/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$4.00 ➝ $4.00
3/25/2025
OncoCyte Co. stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
3/18/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $20.00
3/18/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $21.00
3/17/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CervoMed Inc. stock logo
CRVO
CervoMed
$7.14M10.70N/AN/A$1.30 per share6.75
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
N/AN/AN/AN/A$1.21 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$121.85M0.17N/AN/A$12.77 per share0.26
OncoCyte Co. stock logo
OCX
OncoCyte
$3.84M21.88N/AN/A$2.48 per share1.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CervoMed Inc. stock logo
CRVO
CervoMed
-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
-$12.60MN/A0.00N/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.26%-9.36%-4.82%N/A
OncoCyte Co. stock logo
OCX
OncoCyte
-$27.78M-$3.53N/AN/AN/A-6,122.29%-269.32%-59.71%N/A

Latest NAII, OCX, GNTA, and CRVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million
5/12/2025Q1 2025
OncoCyte Co. stock logo
OCX
OncoCyte
-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million
3/24/2025Q4 2024
OncoCyte Co. stock logo
OCX
OncoCyte
-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million
3/17/2025Q4 2024
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
OncoCyte Co. stock logo
OCX
OncoCyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
15.04
15.04
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
N/A
9.31
N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.70
1.50
OncoCyte Co. stock logo
OCX
OncoCyte
N/A
0.53
0.50

Institutional Ownership

CompanyInstitutional Ownership
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
15.13%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
OncoCyte Co. stock logo
OCX
OncoCyte
55.35%

Insider Ownership

CompanyInsider Ownership
CervoMed Inc. stock logo
CRVO
CervoMed
35.40%
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
28.99%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
OncoCyte Co. stock logo
OCX
OncoCyte
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
CervoMed Inc. stock logo
CRVO
CervoMed
48.70 million3.93 millionNot Optionable
Genenta Science S.p.A. stock logo
GNTA
Genenta Science
718.29 million12.99 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.20 million4.90 millionNot Optionable
OncoCyte Co. stock logo
OCX
OncoCyte
12028.60 million17.18 millionNo Data

Recent News About These Companies

OncoCyte Q1 2025 Earnings Preview
New Strong Buy Stocks for May 6th

New MarketBeat Followers Over Time

Media Sentiment Over Time

CervoMed stock logo

CervoMed NASDAQ:CRVO

$8.78 -0.01 (-0.11%)
Closing price 05/20/2025 04:00 PM Eastern
Extended Trading
$8.74 -0.04 (-0.40%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Genenta Science stock logo

Genenta Science NASDAQ:GNTA

$4.35 +0.05 (+1.16%)
As of 05/20/2025 01:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.28 -0.03 (-0.91%)
As of 05/20/2025 04:00 PM Eastern

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

OncoCyte stock logo

OncoCyte NASDAQ:OCX

$2.94 +0.14 (+5.00%)
Closing price 05/20/2025 03:59 PM Eastern
Extended Trading
$2.78 -0.16 (-5.27%)
As of 08:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.